SARATOGA, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) ...
CapsoVision Inc. held its 2026 Annual Meeting of Stockholders on June 11, 2026, where shareholders voted on director elections and auditor ratification. The meeting outcomes confirm continuity in ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
CapsoVision, Inc. closed its IPO, raising $27.5 million by selling 5.5 million shares at $5 each. CapsoVision, Inc. announced the successful closing of its initial public offering (IPO) on July 3, ...
Hosted on MSN
CapsoVision Q1 earnings call highlights
CapsoVision (NASDAQ:CV) reported steady first-quarter revenue and said it continues to advance artificial intelligence and capsule endoscopy programs aimed at expanding the use of its gastrointestinal ...
Wang stated, "we now expect to submit our 510(k) application for CapsoCam Colon Gen 2 and its AI module in the third quarter of 2026." For the CapsoCam UGI pancreatic cancer initiative, he said, "we ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
SARATOGA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (“AI”) ...
The average one-year price target for CapsoVision (NasdaqCM:CV) has been revised to $6.12 / share. This is an increase of 20.00% from the prior estimate of $5.10 dated November 7, 2025. The price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results